SC
GILD icon

Scotia Capital’s Gilead Sciences GILD Stock Holding History

Scotia Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-30,000
Closed -$2.5M – 800
2016
Q2 		$2.5M Buy
+30,000
New +$2.66M 0.05% 233

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Scotia Capital's GILD Position: Q1 2026 in Review

Scotia Capital increased its Gilead Sciences (GILD) stake by 8.5% in Q1 2026, buying an estimated $1.57M and bringing the position to 142,932 shares worth $19.9M. The position accounts for 0.08% of the portfolio, ranked #137.

Scotia Capital first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $23.2M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Scotia Capital held 142,932 shares of Gilead Sciences worth $19.9M as of Q1 2026.
  • Scotia Capital bought 11,247 Gilead Sciences shares in Q1 2026, an estimated $1.57M.
  • Gilead Sciences made up 0.08% of Scotia Capital's portfolio in Q1 2026, its #137 holding.
  • Scotia Capital first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's Gilead Sciences position peaked at $23.2M in Q2 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.